{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:12:46Z","timestamp":1792699966054,"version":"4.5.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>\n                    <jats:italic>Mycoplasma pneumoniae<\/jats:italic>\n                    is an important pathogen causing upper and lower respiratory tract infections in children and other age groups. Macrolides are the recommended treatments of choice for\n                    <jats:italic>M. pneumoniae<\/jats:italic>\n                    infections. However, macrolide resistance in\n                    <jats:italic>M. pneumoniae<\/jats:italic>\n                    is increasing worldwide, which complicates the treatment strategies. The mechanisms of macrolide resistance have been extensively studied focusing on the mutations in\n                    <jats:italic>23S rRNA<\/jats:italic>\n                    and ribosomal proteins. Since the secondary treatment choice for pediatric patients is very limited, we decided to look for potential new treatment strategies in macrolide drugs and investigate possible new mechanisms of resistance. We performed an\n                    <jats:italic>in vitro<\/jats:italic>\n                    selection of mutants resistant to five macrolides (erythromycin, roxithromycin, azithromycin, josamycin, and midecamycin) by inducing the parent\n                    <jats:italic>M. pneumoniae<\/jats:italic>\n                    strain M129 with increasing concentrations of the drugs. The evolving cultures in every passage were tested for their antimicrobial susceptibilities to eight drugs and mutations known to be associated with macrolide resistance by PCR and sequencing. The final selected mutants were also analyzed by whole-genome sequencing. Results showed that roxithromycin is the drug that most easily induces resistance (at 0.25 mg\/L, with two passages, 23 days), while with midecamycin it is most difficult (at 5.12 mg\/L, with seven passages, 87 days). Point mutations C2617A\/T, A2063G, or A2064C in domain V of\n                    <jats:italic>23S rRNA<\/jats:italic>\n                    were detected in mutants resistant to the 14- and 15-membered macrolides, while A2067G\/C was selected for the 16-membered macrolides. Single amino acid changes (G72R, G72V) in ribosomal protein L4 emerged during the induction by midecamycin. Genome sequencing identified sequence variations in\n                    <jats:italic>dnaK<\/jats:italic>\n                    ,\n                    <jats:italic>rpoC<\/jats:italic>\n                    ,\n                    <jats:italic>glpK<\/jats:italic>\n                    ,\n                    <jats:italic>MPN449<\/jats:italic>\n                    , and in one of the\n                    <jats:italic>hsdS<\/jats:italic>\n                    (\n                    <jats:italic>MPN365<\/jats:italic>\n                    ) genes in the mutants. Mutants induced by the 14- or 15-membered macrolides were resistant to all macrolides, while those induced by the 16-membered macrolides (midecamycin and josamycin) remained susceptible to the 14- and 15-membered macrolides. In summary, these data demonstrated that midecamycin is less potent in inducing resistance than other macrolides, and the induced resistance is restrained to the 16-membered macrolides, suggesting a potential benefit of using midecamycin as a first treatment choice if the strain is susceptible.\n                  <\/jats:p>","DOI":"10.3389\/fcimb.2023.1186017","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:56:30Z","timestamp":1684716990000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":38,"title":["Novel mechanisms of macrolide resistance revealed by in vitro selection and genome analysis in Mycoplasma pneumoniae"],"prefix":"10.3389","volume":"13","author":[{"given":"Na","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaogang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ijantimicag.2017.05.020","article-title":"16-membered macrolide antibiotics: a review","volume":"51","author":"Arsic","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B2","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/j.1574-6976.2008.00129.x","article-title":"Epidemiology, clinical manifestations, pathogenesis and laboratory detection of mycoplasma pneumoniae infections","volume":"32","author":"Atkinson","year":"2008","journal-title":"FEMS Microbiol. Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2174\/1568005054880109","article-title":"Mechanisms of drug resistance in mycoplasma pneumoniae","volume":"5","author":"Bebear","year":"2005","journal-title":"Curr. Drug Targets Infect. Disord."},{"key":"B4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2217\/fmb.11.18","article-title":"Mycoplasma pneumoniae: susceptibility and resistance to antibiotics","volume":"6","author":"B\u00e9b\u00e9ar","year":"2011","journal-title":"Future Microbiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1086\/653535","article-title":"High prevalence of macrolide resistance in mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China","volume":"51","author":"Cao","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1745-7270.2007.00265.x","article-title":"Cloning and characterization of genes encoded in dTDP-d-mycaminose biosynthetic pathway from a midecamycin-producing strain, streptomyces mycarofaciens","volume":"39","author":"Cong","year":"2007","journal-title":"Acta Biochim. Biophys. Sin. (Shanghai)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1128\/AAC.45.1.319-323.2001","article-title":"Mutation in 23S rRNA responsible for resistance to 16-membered macrolides and streptogramins in streptococcus pneumoniae","volume":"45","author":"Depardieu","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.2147\/IDR.S346724","article-title":"Diversity of glpK gene and its effect on drug sensitivity in mycobacterium bovis","volume":"15","author":"Dong","year":"2022","journal-title":"Infect. Drug Resist."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1128\/AAC.45.10.2958-2960.2001","article-title":"Two new point mutations at A2062 associated with resistance to 16-membered macrolide antibiotics in mutant strains of mycoplasma hominis","volume":"45","author":"Furneri","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"B10","doi-asserted-by":"publisher","first-page":"6.4.07","DOI":"10.1128\/microbiolspec.ARBA-0030-2018","article-title":"Antimicrobial resistance in mycoplasma spp","volume":"6","author":"Gautier-Bouchardon","year":"2018","journal-title":"Microbiol. Spectr."},{"key":"B11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12879-015-0781-7","article-title":"Treatment efficacy, treatment failures and selection of macrolide resistance in patients with high load of mycoplasma genitalium during treatment of male urethritis with josamycin","volume":"15","author":"Guschin","year":"2015","journal-title":"BMC Infect. Dis."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/femspd\/ftx017","article-title":"The surface-displayed chaperones GroEL and DnaK of mycoplasma pneumoniae interact with human plasminogen and components of the extracellular matrix","volume":"75","author":"Hagemann","year":"2017","journal-title":"Pathog. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1128\/JB.01103-08","article-title":"Glycerol metabolism is important for cytotoxicity of mycoplasma pneumoniae","volume":"191","author":"Hames","year":"2009","journal-title":"J. Bacteriol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1128\/AAC.38.4.790","article-title":"In vitro and in vivo activities of macrolides against mycoplasma pneumoniae","volume":"38","author":"Ishida","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"4046","DOI":"10.1128\/aac.00663-13","article-title":"Nationwide surveillance of macrolide-resistant mycoplasma pneumoniae infection in pediatric patients","volume":"57","author":"Kawai","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1440-1843.2011.02102.x","article-title":"Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant mycoplasma pneumoniae pneumonia in paediatric patients","volume":"17","author":"Kawai","year":"2012","journal-title":"Respirology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.bjid.2013.09.004","article-title":"Characteristics of hospitalized children infected with macrolide-resistant mycoplasma pneumoniae","volume":"18","author":"Komatsu","year":"2014","journal-title":"Braz. J. Infect. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/14787210.2018.1414599","article-title":"Antimicrobial therapy of macrolide-resistant mycoplasma pneumoniae pneumonia in children","volume":"16","author":"Lee","year":"2018","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222312636","article-title":"Midecamycin is inactivated by several different sugar moieties at its inactivation site","volume":"22","author":"Lin","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1128\/JCM.00678-12","article-title":"Multiclonal origin of macrolide-resistant mycoplasma pneumoniae isolates as determined by multilocus variable-number tandem-repeat analysis","volume":"50","author":"Liu","year":"2012","journal-title":"J. Clin. Microbiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1128\/AAC.39.12.2770","article-title":"Transition mutations in the 23S rRNA of erythromycin-resistant isolates of mycoplasma pneumoniae","volume":"39","author":"Lucier","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2016.00329","article-title":"Infection with and carriage of mycoplasma pneumoniae in children","volume":"7","author":"Meyer Sauteur","year":"2016","journal-title":"Front. Microbiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1128\/AAC.49.6.2302-2306.2005","article-title":"Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation","volume":"49","author":"Morozumi","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/j.1348-0421.2001.tb01293.x","article-title":"Characteristics of macrolide-resistant mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro","volume":"45","author":"Okazaki","year":"2001","journal-title":"Microbiol. Immunol."},{"key":"B25","doi-asserted-by":"crossref","first-page":"325","DOI":"10.7883\/yoken.JJID.2007.325","article-title":"Mycoplasma pneumoniae isolated from patients with respiratory infection in kanagawa prefecture in 1976-2006: emergence of macrolide-resistant strains","volume":"60","author":"Okazaki","year":"2007","journal-title":"Jpn J. Infect. Dis."},{"key":"B26","first-page":"57","article-title":"In vitro subminimum inhibitory concentrations of macrolide antibiotics induce macrolide resistance in mycoplasma pneumoniae","volume":"19","author":"Ou","year":"2015","journal-title":"Hippokratia"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2016.00974","article-title":"Mycoplasma pneumoniae: current knowledge on macrolide resistance and treatment","volume":"7","author":"Pereyre","year":"2016","journal-title":"Front. Microbiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1128\/AAC.48.2.460-465.2004","article-title":"In vitro selection and characterization of resistance to macrolides and related antibiotics in Mycoplasma pneumoniae","volume":"48","author":"Pereyre","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"B29","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1128\/aac.46.2.590-593.2002","article-title":"Characterization of mutations in DNA gyrase and topoisomerase IV involved in quinolone resistance of mycoplasma gallisepticum mutants obtained in vitro","volume":"46","author":"Reinhardt","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"B30","doi-asserted-by":"publisher","first-page":"19665","DOI":"10.1073\/pnas.1907631116","article-title":"Phase variation in mycobacterium tuberculosis glpK produces transiently heritable drug tolerance","volume":"116","author":"Safi","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B31","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1046\/j.1198-743x.2001.00280.x","article-title":"In vitro activity of midecamycin diacetate, a 16-membered macrolide, against streptococcus pyogenes isolated in France 1995-1999","volume":"7","author":"Schlegel","year":"2001","journal-title":"Clin. Microbiol. Infect."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001444","article-title":"Carriage of mycoplasma pneumoniae in the upper respiratory tract of symptomatic and asymptomatic children: an observational study","volume":"10","author":"Spuesens","year":"2013","journal-title":"PloS Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.chembiol.2010.04.008","article-title":"Interplay between the ribosomal tunnel, nascent chain, and macrolides influences drug inhibition","volume":"17","author":"Starosta","year":"2010","journal-title":"Chem. Biol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1128\/iai.00575-08","article-title":"Mycoplasma pneumoniae infection induces reactive oxygen species and DNA damage in A549 human lung carcinoma cells","volume":"76","author":"Sun","year":"2008","journal-title":"Infect. Immun."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064607","article-title":"Multiple-locus variable-number tandem-repeat analysis of mycoplasma pneumoniae clinical specimens and proposal for amendment of MLVA nomenclature","volume":"8","author":"Sun","year":"2013","journal-title":"PloS One"},{"key":"B36","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.vetmic.2017.06.003","article-title":"Mutations in the quinolone resistance determining region conferring resistance to fluoroquinolones in mycoplasma agalactiae","volume":"207","author":"Tatay-Dualde","year":"2017","journal-title":"Vet. Microbiol."},{"key":"B37","first-page":"19","article-title":"Methods for antimicrobial susceptibility testing for human mycoplasmas; approved guideline","volume":"31","author":"Waites","year":"2011","journal-title":"Clin. Lab. Standards Institute"},{"key":"B38","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1128\/CMR.17.4.697-728.2004","article-title":"Mycoplasma pneumoniae and its role as a human pathogen","volume":"17","author":"Waites","year":"2004","journal-title":"Clin. Microbiol. Rev."},{"key":"B39","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1128\/CMR.00114-16","article-title":"Mycoplasma pneumoniae from the respiratory tract and beyond","volume":"30","author":"Waites","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.01890","article-title":"In vitro activities of nemonoxacin and other antimicrobial agents against human mycoplasma and ureaplasmas isolates and their defined resistance mechanisms","volume":"10","author":"Wang","year":"2019","journal-title":"Front. Microbiol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"4443","DOI":"10.2147\/idr.S370126","article-title":"Antimicrobial susceptibility profiles and genetic characteristics of mycoplasma pneumoniae in shanghai, China, from 2017 to 2019","volume":"15","author":"Wang","year":"2022","journal-title":"Infect. Drug Resist."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1093\/jac\/dkaa027","article-title":"In vitro activities of acetylmidecamycin and other antimicrobials against human macrolide-resistant mycoplasma pneumoniae isolates","volume":"75","author":"Wang","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"B43","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1186\/s12864-015-1801-0","article-title":"Comparative genome analysis of mycoplasma pneumoniae","volume":"16","author":"Xiao","year":"2015","journal-title":"BMC Genomics"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1128\/AAC.01563-08","article-title":"Molecular mechanisms of macrolide resistance in clinical isolates of mycoplasma pneumoniae from China","volume":"53","author":"Xin","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2020.104231","article-title":"Subtractive proteomics and systems biology analysis revealed novel drug targets in mycoplasma genitalium strain G37","volume":"145","author":"Yang","year":"2020","journal-title":"Microb. Pathog."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2021.100014","article-title":"Folding non-homologous proteins by coupling deep-learning contact maps with I-TASSER assembly simulations","volume":"1","author":"Zheng","year":"2021","journal-title":"Cell Rep. Methods"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1128\/AAC.04308-14","article-title":"Macrolide-resistant mycoplasma pneumoniae in adults in zhejiang, China","volume":"59","author":"Zhou","year":"2015","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1186017\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T16:49:45Z","timestamp":1729442985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1186017\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,22]]},"references-count":47,"alternative-id":["10.3389\/fcimb.2023.1186017"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2023.1186017","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,22]]},"article-number":"1186017"}}